ProCE Banner Activity

Current Therapeutic Options for Metastatic Pancreatic Cancer: First-line Treatment

Multimedia
This brief activity provides expert insights into the selection of first-line systemic therapy for patients with advanced pancreatic cancer based on best available evidence.

Released: February 17, 2021

Expiration: February 16, 2022

Share

Faculty

Andrew H. Ko

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Ipsen Biopharmaceuticals Inc

Learning Objectives

  • Apply individualized treatment strategies for patients with newly diagnosed pancreatic cancer and for advanced pancreatic cancer following first-line systemic therapy, based on available data and treatment guidelines (maintenance or progression)

  • Examine the emerging role of PARP inhibitors in the frontline maintenance setting for patients with BRCA-mutant pancreatic cancer

  • Counsel patients regarding the incidence and manifestation of adverse events associated with existing/emerging therapies in the management of pancreatic cancer to support quality of life and continuation of therapy

  • Identify patients suitable for enrollment on ongoing clinical studies of emerging investigational agents and treatment strategies in advanced pancreatic cancer

Program Director Disclosure

Program Director

Andrew H. Ko, MD

Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California

Andrew H. Ko, MD, has disclosed that he has received consulting fees from Erytech, Imugene, Ipsen, Roche/Genentech, and SynCore and funds for research support paid to his institution from AbGenomics, Apexigen, Astellas, Bristol-Myers Squibb, Celgene, Merck, and Roche/Genentech.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.